#65
Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
“If cannabis moves to Schedule III, we’ll finally have the research infrastructure and manufacturing standards to answer the clinical questions my patients are actually asking me, but we need to be clear that GMP compliance will raise costs significantly and some patients will lose access before the market stabilizes.”
The potential rescheduling of cannabis to a lower Drug Enforcement Administration category could meaningfully expand research opportunities and clarify manufacturing standards through Good Manufacturing Practice (GMP) requirements, yet clinicians should recognize that regulatory status change alone does not resolve fundamental evidence gaps about efficacy, dosing, and safety profiles across patient populations. Current cannabis products vary substantially in cannabinoid composition, terpene profiles, and contaminant levels regardless of regulatory framework, making standardization through GMP compliance a necessary but insufficient step toward clinical certainty. The gap between regulatory accessibility and robust clinical data means that providers cannot yet rely on rescheduling to automatically improve the evidence base for cannabis in standard practice. In the near term, clinicians should remain cautious about therapeutic claims while staying informed about evolving GMP standards, use available registries and pharmacovigilance systems to track patient outcomes, and recognize that patients may increasingly expect cannabis to be available as a
💬 Join the Conversation
Have a question about how this applies to your situation?
Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers?
Join the forum discussion →
Have thoughts on this? Share it:
Get the next evidence review in your inbox
Plain-language summaries of the newest cannabis research, written by a physician. Free to read, and you can unsubscribe at any time.
Join the growing cannabis community. Free. One-click subscribe. Delivered by Substack.
